

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/062,483	02/05/2002	Baoshan Ku	3519-0115P	2815
2292 75	90 04/18/2003			
	ART KOLASCH &	EXAMINER		
PO BOX 747	TH MA 22040 0747	KIM, VICKIE Y		
ralls chore	CH, VA 22040-0747			
			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 04/18/2003	\wp

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/062,483	KU ET AL.			
Office Action Summary	Examin r	Art Unit			
	Vickie Kim	1614			
The MAILING DATE of this communication appears on the cov r sheet with the correspond nce address Period for R ply					
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a poly within the statutory minimum of third will apply and will expire SIX (6) MON te, cause the application to become Al	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on2a) This action is FINAL.2b) T	——· This action is non-final.				
, <u> </u>		tters prosecution as to the merits is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application	on.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-20 are subject to restriction and/or	r election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on	is: a)□ approved b)□ c	lisapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
 Certified copies of the priority documents have been received. 					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)	J G				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152) .			



Application/Control Number: 10/062,483

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-14, drawn to a method of producing analgesia in a mammal using a synergistic combination of an opioid analgesic and a compound that binds to the SS1 or SS2 subunit of a sodium channel in a pharmaceutically suitable vehicle.
 - II. Claims 15-20, drawn to a pharmaceutical composition of an opioid analgesic and a compound that binds to the SS1 or SS2 subunit of a sodium channel in a pharmaceutically suitable carrier.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)).

Because these inventions are distinct for the reasons given above and the search required for each group is not same, wherein a reference which anticipates the invention of Group I would not render the invention of Group II obvious, absent ancillary art, restriction for examination purposes as indicated is proper. Even if there were unity of classification, the search of entire groups and/or genus in the non-patent

Application/Control Number: 10/062,483

Art Unit: 1614

literature(especially, non-patent literature) and database search (a significant part of a thorough examination) would be burdensome, it is undue burden for examiner for the accurate and proper examination, restriction for examination purposes as indicated is proper.

Election of species

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1 and 15 are generic. Upon the election of the patentably distinct invention of the group, applicant is required further election of species of opioid analgesic agents and a single disclosed species of compounds that binds to the SS1 or SS2 subunit of a sodium channel. It is noted that a reference to one synergistic combination of drugs would not be a reference to another combination of drugs under U.S. C. 103. Further, the claims read on a multitue of enhanced combinations of drugs which would require many field of searches that would be an undue burden on the examiner. Therefore, restriction for examination purposes is proper. The species are recited in claims 2,11, 16, 17 and 18. Applicant is required to elect a single disclosed species(e.g. specific synergistic combination), from under the instant claims of the elected group. Moreover, whatever specific compound is ultimately elected, applicants are required to list all claims readable thereon. With the election of a specific exemplified compound, a generic concept will be identified by the examiner as the inventive group for examination.



Application/Control Number: 10/062,483

Art Unit: 1614

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

3. No claim is allowed. All the pending claims are subject to the restriction/election requirement.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 703-305-1675. The examiner can normally be reached on Tuesday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel

can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-3165 for regular communications and 703-746-3165 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Vickie Kim,

Patent examiner April 11, 2003

Art unit 1614